Genetic conjugation of components in two pneumococcal fusion protein vaccines enhances paediatric mucosal immune responses

Keyphrases

• Conjugation 100%
• Pediatric 100%
• CD4+ T 100%
• Mucosal Immune Response 100%
• Pneumococcal Surface Adhesin A 100%
• Fusion Protein Vaccine 100%
• Pneumolysin 66%
• Antibody Response 33%
• High Concentration 33%
• Cytotoxicity 33%
• Flow Cytometry 33%
• Cell Proliferation 33%
• MHC Class II 33%
• CD4+ T Cells 33%
• Cell Culture 33%
• Meningitis 33%
• Binding Activity 33%
• Membrane Binding 33%
• Streptococcus Pneumoniae 33%
• Cytokine Secretion 33%
• Cell Viability 33%
• Cell Response 33%
• Upper Respiratory Tract 33%
• Proliferative Response 33%
• Cellular Immunity 33%
• Enhanced Response 33%
• Immune Enhancement 33%
• Mononuclear Cells 33%
• Pneumonia 33%
• Next-generation Vaccines 33%
• Otitis Media 33%
• Cytolytic 33%
• Cytolysis 33%
• Pneumococcal Serotypes 33%
• Adjuvant Properties 33%
• Future Vaccines 33%
• Genetic Fusion 33%
• Adjuvanticity 33%
• Pneumococcal Conjugate Vaccine 33%
• Multiplex Technology 33%
• Th17 Profile 33%
• Antipneumococcal 33%
• Primary Immune Cells 33%

Immunology and Microbiology

• T-Helper Cell 100%
• Mucosal Immune Response 100%
• Bacterial Conjugation 100%
• Cytotoxicity 25%
• MHC Class II 25%
• Antibody Response 25%
• Cell Culture 25%
• Cytolysis 25%
• Binding Affinity 25%
• Cytokine Release 25%
• Cell Viability 25%
• Serotype 25%
• Adoptive Immunity 25%
• Upper Respiratory Tract 25%
• Meningitis 25%
• Immunocompetent Cell 25%
• Mononuclear Cell 25%
• Membrane Binding 25%
• Antigen-Presenting Cell 25%
• Adjuvant 25%
• Streptococcus Pneumonia 25%
• Otitis Media 25%
• Pneumococcal Vaccine 25%